Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | UGCG | Q16739 | 9/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18070681 | 0.81 | CYP3A4 (0.40) | CYP3A4CYP11B2CYP17A1UGCGHRH3 | |
| SCHEMBL21123280 | 0.81 | CYP3A4 (0.38) | CYP3A4CYP11B2CYP17A1UGCGPTGS2 | |
| SCHEMBL18069869 | 0.77 | UGCG (0.45) | CYP3A4CYP11B2UGCG | |
| SCHEMBL18070696 | 0.76 | UGCG (0.47) | UGCGNPC1MAPTRAB9A | |
| SCHEMBL19862022 | 0.73 | MAPK10 (0.46) | CYP3A4CYP11B2CYP17A1MAPTHRH3 | |
| SCHEMBL19862036 | 0.73 | PRF1 (0.43) | UGCGPGR | |
| SCHEMBL19862033 | 0.71 | CYP3A4 (0.40) | CYP3A4CYP11B2CYP17A1UGCGMAPT | |
| SCHEMBL1482704 | 0.68 | CYP3A4 (0.51) | CYP3A4CYP11B2CYP17A1HRH3CYP11B1 | |
| SCHEMBL21122856 | 0.68 | CYP3A4 (0.36) | CYP3A4CYP11B2CYP17A1PTGS2NPC1 | |
| SCHEMBL19862020 | 0.68 | UGCG (0.35) | CYP3A4PDE3BPDE3AUGCGNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMECEUTICAL INC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMECEUTICAL INC (US) | 2019-08-15 | — | — | US | disclosed |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759769-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | CYP3A4 3339/4885CYP11B2 1270/4885CYP17A1 713/4885 |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CYP3A4 3339/4885CYP11B2 1270/4885CYP17A1 713/4885 |
| US-20190248754-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | CYP3A4 3339/4885CYP11B2 1270/4885CYP17A1 713/4885 |
| US-10227312-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | CYP3A4 3339/4885CYP11B2 1270/4885CYP17A1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.